About the Corporate Council
The ACAAI Corporate Council offers companies exposure to nearly 6,000 allergists and immunologists, including more than 3,000 who are board-certified by the ABAI. Participation in the Corporate Council also provides valuable access to the ACAAI Board of Regents and other key opinion leaders.
The Corporate Council is comprised of senior executives from pharmaceutical, medical device and other companies involved in the field of allergy and immunology. Two representatives from each participating company will hold seats on the Corporate Council and will be invited to the annual Corporate Council roundtable meeting.
The Council’s goal is to address critical issues in allergy and immunology, find solutions to pressing challenges, share knowledge of best practices and advise members on upcoming initiatives. By pooling resources and expertise, Corporate Council members and the ACAAI leadership can engage in joint problem-solving and explore collaborative opportunities to improve patient care and advance the mission of ACAAI.
To learn more about becoming a member of the ACAAI Corporate Council, please contact:
Linda Cullison
Director of Corporate Relations
American College of Allergy, Asthma & Immunology
Phone: 847-725-2291
Email: lindacullison@acaai.org
Partners
Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Tel: 805-447-1000
https://www.amgen.com
Kyowa Kirin
510 Carnegie Center Drive, Suite 600
Princeton, NJ 08540
Tel: 609-919-1100
https://www.kkna.kyowakirin.com
Amgen and Kyowa Kirin Collaboration
On June 1, 2021, Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-promote the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads.
About Kyowa Kirin
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com.
AstraZeneca
1800 Concord Pike
Wilmington, DE 19850
Tel: 800-236-9933
Tel: 877-810-6060
www.astrazeneca-us.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com.
Blueprint Medicines
45 Sidney Street
Cambridge, MA 02139
Tel: (617) 374-7580
www.blueprintmedicines.com
Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines. Applying an approach that is both precise and agile, we seek to create therapies that selectively target the root cause of disease, with the goal of staying one step ahead across stages of disease.
A core component of our company strategy is extending our leadership position in Systemic Mastocytosis (SM) and expanding it to other mast cell disorders.
We are leveraging our deep understanding of disease biology to drive scientific innovation and then bringing that innovation to patients with our clinical and regulatory know-how. Today, we have brought our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for mast cell disorders, including systemic mastocytosis and chronic urticaria as well as breast cancer and other solid tumors.
For more information, visit https://www.blueprintmedicines.com/medical-professionals/
Chiesi USA, Inc.
175 Regency Woods Place, Ste. 600
Cary, NC 27518
https://www.chiesiusa.com/
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly toward both the community and the environment. With 90 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and has more than 6,500 employees. For further information, please visit www.chiesi.com.
DBV Technologies
25 DeForest Avenue, Suite 203
Summit, NJ 07901
www.dbv-technologies.com
Genentech
1 DNA Way
South San Francisco, CA 94080
www.gene.com
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
GSK
Five Moore Drive
Research Triangle Park, NC 27709
us.gsk.com/en-us/home/
GSK is a science-led global healthcare company with a special purpose: to help people. We research, develop and manufacture innovative pharmaceutical, biological, vaccine, and consumer healthcare products in an effort to bring differentiated, high-quality products, resources, and the science behind it all.
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
www.incyte.com
Insmed Incorporated
700 US Highway 202/206
Bridgewater, NJ 08807
https://insmed.com/
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed’s most advanced programs are in pulmonary and inflammatory conditions. The Company’s early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
https://www.ionis.com/
For more than three decades, Ionis has pioneered RNA-targeted medicines to achieve firsts that were once thought impossible. We have multiple marketed medicines and a leading pipeline in neurology, cardiology and other areas of high patient need. Our pipeline is fueled by relentless innovation of our science and technology, enhancing the profiles of our existing RNA-targeted medicines and unlocking new opportunities in emerging areas. Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.
Kaléo
111 Virginia Street, Suite 300
Richmond, VA 23219
https://www.kaleo.com/
Kaléo is a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions that can help protect and empower patients to live fuller, bolder lives. Our commitment to creating innovative healthcare solutions has set the standard for drug-device combination product development. The company’s advanced manufacturing techniques and forward-thinking Human Factors Engineering approach allow us to effectively address the unmet needs of patients and the pharmaceutical industry. Kaléo is a privately held company headquartered in Richmond VA. Visit www.kaleo.com to learn more about our innovative healthcare solutions.
KalVista Pharmceuticals
55 Cambridge Parkway
Suite 901E
Cambridge, MA 02142
https://www.kalvista.com/
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities.
For more information about KalVista, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.
Novartis Pharmaceuticals Corporation
One Health Plaza
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Follow us at https://www.novartis.com, also on Twitter, Facebook and LinkedIn
Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers over 70 medicines and products in women’s health, dermatology, biosimilars, and a large franchise of established medicines across a range of therapeutic areas.
Learn more about us at Organon.com.
Pharming Healthcare, Inc.
685 Route 202/206, Suite 202
Bridgewater, NJ 08807
Tel: 800-930-5221
www.pharming.com
Pharming Healthcare, Inc. is dedicated to providing life-changing solutions to patients. Pharming is currently involved in the development of drugs for the treatment of hereditary angioedema and has marketing operations in the United States, Israel, all 28 European Union countries plus Norway, Iceland, and Liechtenstein.
Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807
www.sanofi.us/en
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill Road
Tarrytown, NY 10591-6707
www.regeneron.com
Since 2007, Sanofi and Regeneron have collaborated to help people with conditions that are often difficult to diagnose and treat, using innovative technology platforms. Sanofi is an innovative global healthcare company that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Headquartered in North Carolina, Stallergenes Greer’s business in the United States is part of a leading global biopharmaceutical company specializing in the development and commercialization of allergy immunotherapy (AIT) products and services for use in the diagnosis and treatment of allergies.
Takeda Pharmaceutical Company Limited
650 Kendall Street
Cambridge, MA 02142
www.takeda.com
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit www.takeda.com.
